OTCMKTS:SDZNY Sandoz Group (SDZNY) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free SDZNY Stock Alerts $32.80 -0.84 (-2.50%) (As of 04/26/2024 08:54 PM ET) Add Compare Share Share Today's Range$32.48▼$32.9950-Day Range$27.81▼$34.0252-Week Range$25.71▼$34.94Volume256,000 shsAverage Volume173,812 shsMarket Capitalization$14.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Sandoz Group alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Sandoz Group Stock (OTCMKTS:SDZNY)Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.Read More SDZNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SDZNY Stock News HeadlinesApril 29, 2024 | msn.comAmgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelledApril 22, 2024 | markets.businessinsider.comSandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology TreatmentsApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...April 22, 2024 | globenewswire.comSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringMarch 21, 2024 | globenewswire.comSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesMarch 14, 2024 | msn.comSandoz Group Non-GAAP EPS of $2.20, revenue of $9.65B; initiates FY24 and long-term outlookMarch 13, 2024 | theglobeandmail.comThe Cultivated B Introduces n!Biomachines: Fit-For-Purpose Bioreactors Designed to Easily and Affordably Scale Cellular AgricultureMarch 13, 2024 | globenewswire.comSandoz reports fourth quarter 2023 sales and full-year 2023 resultsApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...March 6, 2024 | finanznachrichten.deSandoz Group: Sandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | globenewswire.comSandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | finanznachrichten.deSandoz Group: Sandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | finance.yahoo.comSandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | globenewswire.comSandoz announces nominations to the Board of Directors and leadership changeMarch 4, 2024 | globenewswire.comSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketFebruary 29, 2024 | msn.comGeneric/Biosimilar Player Sandoz Settles US Price Fixing Case For $265MFebruary 29, 2024 | finanznachrichten.deSandoz Group: Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsFebruary 29, 2024 | money.usnews.comSandoz Enters $265 Million Settlement Agreement in U.S. Price-Fixing CaseFebruary 29, 2024 | markets.businessinsider.comSandoz US Settles Antitrust Class Action Litigation With Direct Purchaser Class Plaintiffs February 29, 2024 | reuters.comSandoz enters $265 mln settlement agreement in U.S. price-fixing caseFebruary 29, 2024 | globenewswire.comSandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsFebruary 20, 2024 | finance.yahoo.comSandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosisFebruary 1, 2024 | finance.yahoo.comSandoz announces changes in the Board of DirectorsJanuary 22, 2024 | finanznachrichten.deSandoz Group: Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketJanuary 22, 2024 | finance.yahoo.comSandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketNovember 27, 2023 | finance.yahoo.comSandoz Canada announces first ever list of Top 100 most important medicines, from a clinical standpoint, for Canadian patientsNovember 21, 2023 | markets.businessinsider.comSandoz Unveils Hyrimoz Citrate-free High Concentration Formulation In EuropeSee More Headlines Receive SDZNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sandoz Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:SDZNY CUSIPN/A CIKN/A Webwww.sandoz.com Phone41-61-324-11-11FaxN/AEmployees22,633Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio12.57 P/E Growth0.74Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.49 Current Ratio1.33 Quick Ratio0.86 Sales & Book Value Annual Sales$9.65 billion Price / Sales1.47 Cash Flow$2.21 per share Price / Cash Flow14.83 Book Value$20.08 per share Price / Book1.63Miscellaneous Outstanding Shares431,000,000Free FloatN/AMarket Cap$14.14 billion OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Richard Saynor (Age 57)Chief Executive Officer Mr. Colin Michael Bond (Age 64)Chief Financial Officer Mr. Asaf Gal (Age 55)Chief Technology Officer Ms. Claire D'Abreu-Hayling (Age 60)Chief Scientific Officer Ms. Karen M. KingHead Global Investor RelationsMs. Ingrid Sollerer (Age 50)General Counsel & Chief Compliance Officer Ms. Tripti Jha (Age 47)Chief People Officer Mr. Francisco Ballester (Age 63)President of International Mr. Pierre Bourdage (Age 45)Chief Commercial Officer Dr. Glenn A. Gerecke Ph.D. (Age 65)Chief Manufacturing & Supply Officer More ExecutivesKey CompetitorsShionogi & Co., Ltd.OTCMKTS:SGIOYEurofins ScientificOTCMKTS:ERFSFEisaiOTCMKTS:ESALYSysmexOTCMKTS:SSMXYRamsay Health CareOTCMKTS:RMYHYView All Competitors SDZNY Stock Analysis - Frequently Asked Questions Should I buy or sell Sandoz Group stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sandoz Group in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SDZNY shares. View SDZNY analyst ratings or view top-rated stocks. How have SDZNY shares performed in 2024? Sandoz Group's stock was trading at $32.01 on January 1st, 2024. Since then, SDZNY stock has increased by 2.5% and is now trading at $32.80. View the best growth stocks for 2024 here. What ETFs hold Sandoz Group's stock? ETFs with the largest weight of Sandoz Group (OTCMKTS:SDZNY) stock in their portfolio include Franklin FTSE Switzerland ETF (FLSW).Horizon Kinetics Medical ETF (MEDX). How do I buy shares of Sandoz Group? Shares of SDZNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SDZNY) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sandoz Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
